title: Response to Letter From Ruan and Bumgarner: Breakthrough Pain Associated With a Reduction in Serum Buprenorphine Concentration During Dialysis.
authors.affiliation: Department of Clinical Pharmacology and Toxicology, University and University Hospital Basel, Switzerland; Medical University Department, University of Basel, Kantonsspital Aarau Aarau, Switzerland.
authors.forename: Ali Reza
authors.initials: AR
authors.lastname: Salili
authors.affiliation: Institute of Clinical Chemistry, University Hospital Zürich Zürich, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Müller
authors.affiliation: Institute of Clinical Chemistry, University Hospital Basel Basel, Switzerland.
authors.forename: Roswitha
authors.initials: R
authors.lastname: Skendaj
authors.forename: Andreas W
authors.initials: AW
authors.lastname: Jehle
authors.affiliation: Clinic for Transplantation Immunology & Nephrology, University Hospital Basel Basel, Switzerland.
authors.forename: Anne B
authors.initials: AB
authors.lastname: Taegtmeyer
mesh_terms: D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000627:therapeutic use; D059390:Breakthrough Pain; D002047:Buprenorphine; D006801:Humans; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement; D006435:Renal Dialysis
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine